Bill Text: NH SB559 | 2024 | Regular Session | Introduced
Bill Title: Relative to the New Hampshire vaccine association.
Spectrum: Partisan Bill (Democrat 9-0)
Status: (Passed) 2024-07-30 - Signed by the Governor on 07/26/2024; Chapter 0307; Effective 07/26/2024 [SB559 Detail]
Download: New_Hampshire-2024-SB559-Introduced.html
SB 559-FN - AS INTRODUCED
2024 SESSION
24-3113
05/08
SENATE BILL 559-FN
AN ACT relative to the definition of vaccine for purposes of the New Hampshire vaccine association.
SPONSORS: Sen. Prentiss, Dist 5; Sen. Fenton, Dist 10; Sen. Watters, Dist 4; Sen. Altschiller, Dist 24; Sen. Rosenwald, Dist 13; Sen. Perkins Kwoka, Dist 21; Sen. Whitley, Dist 15; Sen. Chandley, Dist 11; Rep. Merchant, Sull. 6
COMMITTEE: Health and Human Services
─────────────────────────────────────────────────────────────────
ANALYSIS
This bill revises the definition of vaccine for purposes of the New Hampshire vaccine association.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Explanation: Matter added to current law appears in bold italics.
Matter removed from current law appears [in brackets and struckthrough.]
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.
24-3113
05/08
STATE OF NEW HAMPSHIRE
In the Year of Our Lord Two Thousand Twenty Four
AN ACT relative to the definition of vaccine for purposes of the New Hampshire vaccine association.
Be it Enacted by the Senate and House of Representatives in General Court convened:
1 New Hampshire Vaccine Association; Definition of Vaccine. RSA 126-Q:1, XI is repealed and reenacted to read as possible:
XI. "Vaccine" means, for the purposes of this chapter, any immunization administered through vaccination that has been approved by the federal Food and Drug Administration and recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention to be added to the Vaccines for Children program and has been authorized by the commissioner of the department of health and human services for administration to children of the state of New Hampshire under the age of 19 years for the purposes of protecting against diseases caused by infectious pathogens.
2 Effective Date. This act shall take effect 60 days after its passage.
24-3113
Revised 1/30/24
SB 559-FN- FISCAL NOTE
AS INTRODUCED
AN ACT relative to the definition of vaccine for purposes of the New Hampshire vaccine association.
FISCAL IMPACT: [ X ] State [ ] County [ ] Local [ ] None
|
| |||||
Estimated State Impact - Increase / (Decrease) | ||||||
| FY 2024 | FY 2025 | FY 2026 | FY 2027 | ||
Revenue | $0 | $717,000 - $1,700,000 | $746,000 - $1,768,000 | $776,000 - $1,839,000 | ||
Revenue Fund(s) | Assessments collected by the NH Vaccine Association | |||||
Expenditures | $0 | $717,000 - $1,700,000 | $746,000 - $1,768,000 | $776,000 - $1,839,000 | ||
Funding Source(s) | Assessments collected by the NH Vaccine Association | |||||
Appropriations | $0 | $0 | $0 | $0 | ||
Funding Source(s) | None | |||||
• Does this bill provide sufficient funding to cover estimated expenditures? [X] See Below • Does this bill authorize new positions to implement this bill? [X] No | ||||||
METHODOLOGY:
This bill revises the definition of "vaccine" in RSA 126-Q, the statute governing the NH Vaccine Association (NHVA). The Department of Health and Human Services states that there is one immunization, nirsevimab (Beyfortus™), which is not currently eligible for procurement with NHVA funds that would immediately become eligible if the bill is enacted. The immunization in question has been approved and recommended by various federal entities (Food and Drug Administration, Centers for Disease Control and Prevention) for the prevention of severe disease caused by respiratory syncytial virus (RSV). The Department notes that the current contracted price for nirsevimab is $395. If it became eligible for purchase with NHVA funds, the following annual increases in revenue (in the form of an assessment on commercial insurers under the mechanism described in RSA 126-Q) and expenditures may occur, depending on the immunization uptake rate:
- If 30 percent uptake: $717,000
- If 50 percent uptake: $1,200,000
- If 70 percent uptake: $1,700,000
The Department assumes that the purchase price of the immunizations will increase by approximately 4 percent per year. The Department further assumes that an unknown number of future immunizations may also become eligible for NHVA purchase under the new definition contained in the bill.
The Insurance Department states that the bill's fiscal impact is indeterminable.
AGENCIES CONTACTED:
Department of Health and Human Services and Insurance Department
